AXQ Capital LP Takes Position in Royalty Pharma PLC $RPRX

AXQ Capital LP purchased a new stake in Royalty Pharma PLC (NASDAQ:RPRX) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 12,198 shares of the biopharmaceutical company’s stock, valued at approximately $471,000.

A number of other large investors have also recently bought and sold shares of RPRX. Lloyd Advisory Services LLC. purchased a new position in Royalty Pharma during the 4th quarter worth $30,000. Smartleaf Asset Management LLC increased its stake in Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 790 shares during the period. Private Trust Co. NA raised its holdings in shares of Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 288 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of Royalty Pharma by 31.9% in the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 306 shares during the last quarter. Finally, Fifth Third Bancorp boosted its stake in shares of Royalty Pharma by 16.9% during the third quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 362 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Price Performance

Shares of RPRX opened at $54.97 on Thursday. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The stock’s 50 day moving average is $50.44 and its two-hundred day moving average is $44.82. Royalty Pharma PLC has a twelve month low of $33.25 and a twelve month high of $56.07. The firm has a market capitalization of $31.65 billion, a PE ratio of 37.39, a P/E/G ratio of 1.48 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. The business had revenue of $630.58 million during the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. Research analysts anticipate that Royalty Pharma PLC will post 5.05 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $0.235 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.94 annualized dividend and a yield of 1.7%. Royalty Pharma’s dividend payout ratio is presently 63.95%.

Insider Buying and Selling at Royalty Pharma

In other Royalty Pharma news, CFO Terrance P. Coyne sold 64,399 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $53.98, for a total transaction of $3,476,258.02. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $52.75, for a total transaction of $721,831.00. Following the transaction, the executive vice president directly owned 18,197 shares in the company, valued at approximately $959,891.75. This trade represents a 42.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 199,185 shares of company stock valued at $10,082,926. 18.84% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on RPRX shares. The Goldman Sachs Group reissued a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. Morgan Stanley upped their price objective on Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research note on Friday, April 10th. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. Finally, Weiss Ratings cut Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 15th. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $53.71.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.